A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA

Abstract Background Early screening for prostate cancer (PCA) remains controversial because of overdiagnosis and overtreatment of clinically insignificant cancers. Even though a number of diagnostic tests have been developed to improve on PSA testing, there remains a need for a more informative non-...

Full description

Bibliographic Details
Main Authors: Igor Brikun, Deborah Nusskern, Andrew Decatus, Eric Harvey, Lin Li, Diha Freije
Format: Article
Language:English
Published: BMC 2018-07-01
Series:Clinical Epigenetics
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13148-018-0524-x
id doaj-b8c5a432ba404a3bb7b91a2e03b7e853
record_format Article
spelling doaj-b8c5a432ba404a3bb7b91a2e03b7e8532020-11-25T00:21:37ZengBMCClinical Epigenetics1868-70751868-70832018-07-0110111510.1186/s13148-018-0524-xA panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNAIgor Brikun0Deborah Nusskern1Andrew Decatus2Eric Harvey3Lin Li4Diha Freije5Euclid Diagnostics LLCEuclid Diagnostics LLCBioStat Solutions Inc.Health Decisions Inc.BioStat Solutions Inc.Euclid Diagnostics LLCAbstract Background Early screening for prostate cancer (PCA) remains controversial because of overdiagnosis and overtreatment of clinically insignificant cancers. Even though a number of diagnostic tests have been developed to improve on PSA testing, there remains a need for a more informative non-invasive test for PCA. The objective of this study is to identify a panel of DNA methylation markers suitable for a non-invasive diagnostic test from urine DNA collected following a digital rectal exam (DRE) and/or from first morning void (FV). A secondary objective is to determine if the cumulative methylation is indicative of biopsy findings. Methods DRE and FV urine samples were prospectively collected from 94 patients and analyzed using 24 methylation-specific quantitative PCR assays derived from 19 CpG islands. The methylation of individual markers and various combinations of markers was compared to biopsy results. A methylation threshold for cancer classification was determined using a target specificity of 70%. The average methylation and the number of positive markers were also compared to the result of the biopsy, and the area under the receiver operating characteristic curves (AUCs) were calculated. Results Methylation of all 19 markers was detected in FV and DRE DNAs. Combining the methylation of two or more markers improved on individual marker results. Using 6of19 methylated markers as the threshold for cancer classification yielded a specificity of 71% (95% CI, 0.57–0.86) from both DRE and FV and a sensitivity of 89% (95% CI, 0.79–0.97) from DRE and 94% (95% CI, 0.84–1.0) from FV. The negative predictive value at the 6of19 threshold was ≥ 90 for both DNA types. Conclusions PCA-specific methylation was detected in both FV and DRE DNA. There was no significant difference in diagnostic accuracy at the 6of19 threshold between DRE and FV urine DNA. The results support the development of a non-invasive diagnostic test to reduce unnecessary biopsies in men with elevated PSA. The test can also provide patients with personalized recommendations based on their own methylation profile.http://link.springer.com/article/10.1186/s13148-018-0524-xProstate cancerDNA methylationUrine biomarkerLiquid biopsyCirculating DNA
collection DOAJ
language English
format Article
sources DOAJ
author Igor Brikun
Deborah Nusskern
Andrew Decatus
Eric Harvey
Lin Li
Diha Freije
spellingShingle Igor Brikun
Deborah Nusskern
Andrew Decatus
Eric Harvey
Lin Li
Diha Freije
A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA
Clinical Epigenetics
Prostate cancer
DNA methylation
Urine biomarker
Liquid biopsy
Circulating DNA
author_facet Igor Brikun
Deborah Nusskern
Andrew Decatus
Eric Harvey
Lin Li
Diha Freije
author_sort Igor Brikun
title A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA
title_short A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA
title_full A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA
title_fullStr A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA
title_full_unstemmed A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA
title_sort panel of dna methylation markers for the detection of prostate cancer from fv and dre urine dna
publisher BMC
series Clinical Epigenetics
issn 1868-7075
1868-7083
publishDate 2018-07-01
description Abstract Background Early screening for prostate cancer (PCA) remains controversial because of overdiagnosis and overtreatment of clinically insignificant cancers. Even though a number of diagnostic tests have been developed to improve on PSA testing, there remains a need for a more informative non-invasive test for PCA. The objective of this study is to identify a panel of DNA methylation markers suitable for a non-invasive diagnostic test from urine DNA collected following a digital rectal exam (DRE) and/or from first morning void (FV). A secondary objective is to determine if the cumulative methylation is indicative of biopsy findings. Methods DRE and FV urine samples were prospectively collected from 94 patients and analyzed using 24 methylation-specific quantitative PCR assays derived from 19 CpG islands. The methylation of individual markers and various combinations of markers was compared to biopsy results. A methylation threshold for cancer classification was determined using a target specificity of 70%. The average methylation and the number of positive markers were also compared to the result of the biopsy, and the area under the receiver operating characteristic curves (AUCs) were calculated. Results Methylation of all 19 markers was detected in FV and DRE DNAs. Combining the methylation of two or more markers improved on individual marker results. Using 6of19 methylated markers as the threshold for cancer classification yielded a specificity of 71% (95% CI, 0.57–0.86) from both DRE and FV and a sensitivity of 89% (95% CI, 0.79–0.97) from DRE and 94% (95% CI, 0.84–1.0) from FV. The negative predictive value at the 6of19 threshold was ≥ 90 for both DNA types. Conclusions PCA-specific methylation was detected in both FV and DRE DNA. There was no significant difference in diagnostic accuracy at the 6of19 threshold between DRE and FV urine DNA. The results support the development of a non-invasive diagnostic test to reduce unnecessary biopsies in men with elevated PSA. The test can also provide patients with personalized recommendations based on their own methylation profile.
topic Prostate cancer
DNA methylation
Urine biomarker
Liquid biopsy
Circulating DNA
url http://link.springer.com/article/10.1186/s13148-018-0524-x
work_keys_str_mv AT igorbrikun apanelofdnamethylationmarkersforthedetectionofprostatecancerfromfvanddreurinedna
AT deborahnusskern apanelofdnamethylationmarkersforthedetectionofprostatecancerfromfvanddreurinedna
AT andrewdecatus apanelofdnamethylationmarkersforthedetectionofprostatecancerfromfvanddreurinedna
AT ericharvey apanelofdnamethylationmarkersforthedetectionofprostatecancerfromfvanddreurinedna
AT linli apanelofdnamethylationmarkersforthedetectionofprostatecancerfromfvanddreurinedna
AT dihafreije apanelofdnamethylationmarkersforthedetectionofprostatecancerfromfvanddreurinedna
AT igorbrikun panelofdnamethylationmarkersforthedetectionofprostatecancerfromfvanddreurinedna
AT deborahnusskern panelofdnamethylationmarkersforthedetectionofprostatecancerfromfvanddreurinedna
AT andrewdecatus panelofdnamethylationmarkersforthedetectionofprostatecancerfromfvanddreurinedna
AT ericharvey panelofdnamethylationmarkersforthedetectionofprostatecancerfromfvanddreurinedna
AT linli panelofdnamethylationmarkersforthedetectionofprostatecancerfromfvanddreurinedna
AT dihafreije panelofdnamethylationmarkersforthedetectionofprostatecancerfromfvanddreurinedna
_version_ 1725361812210188288